Abbvie Inc ABBV:NYSE

Last Price$142.08NYSE Closing Price as of 6:30PM ET 8/11/22
NYSE 15-minute delayed Bid/Ask Quotes
Today's Change+1.14(0.81%)
Bid (Size)$142.00 (5)
Ask (Size)$142.90 (5)
Day Low / High$139.66 - 142.87
Volume6.0 M

View Pharmaceuticals: Major IndustryPeer Comparison as of 08/11/2022


Abbvie Inc ( NYSE )

Price: $142.08
Change: +1.14 (0.81%)
Volume: 6.0 M
6:30PM ET 8/11/2022

Merck & Co Inc ( NYSE )

Price: $88.93
Change: -0.26 (0.29%)
Volume: 7.4 M
6:30PM ET 8/11/2022

Pfizer Inc ( NYSE )

Price: $48.30
Change: -1.65 (3.30%)
Volume: 44.0 M
4:00PM ET 8/11/2022

Eli Lilly and Co ( NYSE )

Price: $301.17
Change: -3.44 (1.13%)
Volume: 2.2 M
6:30PM ET 8/11/2022

Bristol-Myers Squibb Co ( NYSE )

Price: $74.46
Change: -0.40 (0.53%)
Volume: 6.1 M
6:30PM ET 8/11/2022

Read more news Recent News

AbbVie's Allergan Aesthetics Gets FDA Approval for Gel to Improve Jawline Definition
10:07AM ET 8/03/2022 MT Newswires

AbbVie's (ABBV) Allergan Aesthetics unit said Wednesday the US Food and Drug Administration approved its Juvederm Volux XC injectable gel to improve...

--Goldman Sachs Adjusts AbbVie's Price Target to $137 from $141, Keeps Neutral Rating
1:40PM ET 8/01/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

AbbVie's Neutral Rating Maintained at Goldman Even as Skyrizi Sales Jump
1:02PM ET 8/01/2022 MT Newswires

AbbVie's (ABBV) neutral rating at Goldman Sachs was maintained despite Q2 sales of plaque psoriasis drug Skyrizi significantly outperforming the firm's...

--UBS Adjusts AbbVie Price Target to $146 From $154, Maintains Neutral Rating
11:44AM ET 8/01/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

View all Commentary and Analysis

My Dividend Stock Portfolio: July 2022 Update - 101 Holdings With 22 Buys
8:30AM ET 8/11/2022 Seeking Alpha

Will FHLC Keep Your Portfolio Fit?
2:35PM ET 8/09/2022 Seeking Alpha

RDIV: Outperforming In 2022, But Volatility Is Concerning
8:00AM ET 8/09/2022 Seeking Alpha

Buy 4 S&P 500 August Dog Days Dividend Aristocrats
10:15PM ET 8/08/2022 Seeking Alpha

Company Profile

Business DescriptionAbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL. View company web site for more details
Address1 North Waukegan Road
North Chicago, Illinois 60064-6400
Number of Employees30,000
Recent SEC Filing08/04/202210-Q
Chairman & Chief Executive OfficerRichard A. Gonzalez
Vice Chairman & PresidentRobert A. Michael
Executive Vice President-OperationsAzita Saleki-Gerhardt
Chief Financial Officer & Senior Vice PresidentScott T. Reents

Company Highlights

Price Open$140.23
Previous Close$140.94
52 Week Range$105.56 - 175.91
Market Capitalization$251.2 B
Shares Outstanding1.8 B
SectorHealth Technology
IndustryPharmaceuticals: Major
Current Dividend / Yield$1.41 / 4.00%
Dividend Ex-Date07/14/2022
Dividend Pay-Date08/15/2022
Dividend Yield 5 Year Average4.08%
Next Earnings Announcement11/04/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings19.80
Earnings per Share$6.90
Beta vs. S&P 500N/A
Revenue$32.8 B
Net Profit Margin22.18%
Return on Equity87.05%

Analyst Ratings as of 07/29/2022

Consensus RecommendationConsensus Icon
Powered by Factset